Quarterly report [Sections 13 or 15(d)]

Note 5 - Stock Incentive Plan (Details Textual)

v3.25.3
Note 5 - Stock Incentive Plan (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Aug. 05, 2024
Mar. 31, 2022
Apr. 30, 2020
Mar. 31, 2025
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Aug. 12, 2024
Jun. 30, 2024
Oct. 31, 2017
Apr. 30, 2016
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) [1]               248,381          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value         $ 33,000,000     $ 33,000,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested         $ 10,600,000     $ 10,600,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)         $ 26.67     $ 26.67          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price (in dollars per share)         25.35     25.35          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)         $ 29.28     $ 29.28          
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount         $ 8,600,000     $ 8,600,000          
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)             3 years            
Share-Based Payment Arrangement, Expense, Tax Benefit               0          
General and Administrative Expense [Member]                          
Share-Based Payment Arrangement, Expense         617,413 $ 13,512   2,043,890 $ 325,589        
Research and Development Expense [Member]                          
Share-Based Payment Arrangement, Expense         $ 481,797 $ 185,609   $ 1,689,883 $ 536,584        
Vesting Immediately [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)               8,270          
Vesting Monthly Over One Year [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)               2,000          
Vesting Quarterly Over One Year [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)               51,143          
Vesting 6/48ths on Six-months and 1/48th After [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)               186,968          
Restricted Stock Units (RSUs) [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) [2]               120,941          
Restricted Stock Units (RSUs) [Member] | Vesting Immediately [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)               6,002          
Restricted Stock Units (RSUs) [Member] | Vesting 6/48ths on Six-months and 3/48th Per Quarter After [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)               114,939          
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 7,100,000 1,020,000 620,000             1,420,000 5,100,000 320,000 140,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)   400,000 300,000                    
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)               10 years          
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)               4 years          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 1,420,000                        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 400,000     400,000                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)               248,381          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)         $ 22     $ 22          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]                          
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)         $ 44.96     $ 44.96          
[1] 248,381 options vest as follows: options to purchase 8,270 shares of the Company’s common stock vesting immediately upon the grant date; options to purchase 2,000 shares of the Company’s common stock vesting monthly over one year; options to purchase 51,143 shares of the Company’s common stock vesting quarterly over one year; options to purchase 186,968 shares of the Company’s common stock vesting 6/48ths on the six-month anniversary of the vesting commencement date and 1/48th per month thereafter.
[2] In aggregate, there were 120,941 restricted stock units granted during the nine months ended September 30, 2025, of which 6,002 restricted stock units vested immediately upon the grant date and 114,939 restricted stock units vest 6/48ths on the six-month anniversary of the vesting commencement date and 3/48ths per quarter thereafter.